Innate Pharma SA Sponsored ADR (IPHA) Stock Price

1.43 ▼ -0.08 (-5.30%)
Open: 1.46 Vol: 25.44K Day's range: 1.39 - 1.47 Apr 22, 16:00 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
IPHA Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.61▼ 1.61▼ 1.61▼ 1.56▼ 1.43▼
MA10 1.66▼ 1.65▼ 1.65▼ 1.54▼ 1.48▼
MA20 1.66▼ 1.56▼ 1.53▲ 1.44▼ 1.63▼
MA50 1.47▲ 1.42▲ 1.41▲ 1.52▼ 1.85▼
MA100 1.46▲ 1.53▼ 1.54▼ 1.66▼ 1.96▼
MA200 1.60▼ 1.65▼ 1.67▼ 1.83▼ 2.35▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.028▼ -0.010▼ -0.001▼ 0.016▲ -0.007▼
RSI 40.914▼ 49.489▼ 51.279▲ 46.454▼ 42.510▼
STOCH 0.000▼ 26.061     54.747     55.814     33.382    
WILL %R -100.000▼ -57.576     -57.576     -74.419     -63.889    
CCI -208.939▼ -78.058     -35.595     -47.369     -35.928    
Latest Filters Detected On IPHA
RSI $IPHA RSI(14) Crossed Below 50 Set Alert
MA $IPHA Price Crossed Below MA(13) Set Alert
▼ GAP $IPHA Open Gap Down %3 Set Alert
▼ GAP $IPHA Open Gap Down %2 Set Alert
Innate Pharma SA Sponsored ADR News
Innate Pharma to Participate in the D. Boral Capital Global Conference
Thursday, April 23, 2026 01:32 AM
Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced ...
Innate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global Conference
Thursday, April 23, 2026 01:03 AM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced ...
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Friday, April 17, 2026 12:13 PM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab ...
IPHA historical stock data
date open high low close volume
22/04/26 1.46 1.47 1.39 1.43 25,444
21/04/26 1.5301 1.56 1.51 1.51 7,893
20/04/26 1.63 1.65 1.57 1.59 13,777
17/04/26 1.6101 1.7079 1.6006 1.66 50,318
16/04/26 1.69 1.69 1.62 1.62 55,522
15/04/26 1.73 1.75 1.64 1.69 11,945
14/04/26 1.53 1.71 1.53 1.63 65,170
13/04/26 1.40 1.475 1.39 1.44 13,470
10/04/26 1.42 1.45 1.41 1.41 46,325
09/04/26 1.44 1.45 1.42 1.45 61,025
Quote Details
52wk Low:1.17
52wk High:2.63
Vol:25.44K
Avg Vol(3m):423.6K
1Y Chng:-39.80%
1M Chng:-7.74%
Add to Watch List
More Information
Index US Composite
Market Cap. 141.68M